ArticleBioscience reports2026
Metataxonomic strategy to decipher gut bacteriome biomarkers of type 2 diabetes and obesity in Tunisian population.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic disorders are multifactorial diseases and major global health concerns, with many individuals worldwide responding inadequately to treatments. The gut bacteriome regulates metabolism and offers therapeutic potential; however, research from North Africa remains scarce despite the growing prevalence of non-communicable diseases in the region. This study examines gut bacterial profiles of Tunisian type 2 diabetic (T2D), obese (OB), and non-diabetic (ND) individuals within the framework of personalized medicine. Ninety-five participants were enrolled [33 ND, 26 T2D, 26 T2D with obesity and cardiovascular complications (T2D_OBCV) and 10 OB]. Bacterial 16S rDNA V3-V4 regions were sequenced on Illumina MiSeq and analyzed using the QIIME 2 pipeline. Obese subjects exhibited gut dysbiosis with lower Akkermansia (P=0.02) and Ligilactobacillus (P=0.04) levels, an enrichment of Bifidobacterium (P=0.004), as well as Sutterella (P=0.03) and Erysipelatoclostridium (P=0.02). However, the gut bacteriome landscape of T2D patients reveals differences in the distribution of Shigella (P=0.01) highly abundant in the intestine, and a depletion of Clostridia vadin BB 60 group (P=0.02) and Oscillospiraceae UCG 005 (P=0.01). Noting that the gut bacteriome of T2D_OBCV patients is characterized by a depletion of Asteroleplasma (P=0.01), Oscillospiraceae UCG 005 (P=0.02), Eubacterium ruminantium group (P=0.0007) and Romboutsia (P=0.002) beside an enrichment of Fusicatenibacter (P=0.02). Gut bacteriome alterations in Tunisian T2D and obese subjects may serve as metabolic biomarkers.
Indexed as
Identifiers
42776149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.